Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib with metronomic cyclophosphamide, capecitabine, and low-dose aspirin in metastatic colorectal cancer
2020-002344-23Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Jun 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib, cyclophosphamide, capecitabine and aspirin in colorectal cancer (CRC), sponsored by CHU de Besançon. Primary endpoint: Objective response rate. Started Jun 2020; status: completed.
02
Drugs
regorafenibcyclophosphamidecapecitabineaspirin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-002344-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002344-23.